Effectiveness of Treatments for Advanced Non-Clear Cell Renal Cell Carcinoma
Author Information
Author(s): Zhang Yaping, Chen Jian, Wang Xiaoyan, Wang Hui, Chen Xiaoli, Hong Jianfeng, Fang Hongming
Primary Institution: Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, China
Hypothesis
This study aimed to compare the efficacy of current mainstream drug treatments for non-clear cell renal cell carcinoma (nccRCC) to provide clinical treatment guidance for advanced cases.
Conclusion
The study demonstrates that VEGFR-TKIs improve progression-free survival in first-line treatment compared to mTORi, and combination therapies yield better overall response rates and disease control rates.
Supporting Evidence
- VEGFR-TKIs significantly improved progression-free survival compared to mTORi in first-line treatment.
- Combination therapies showed better overall response rates and disease control rates than single-agent therapies.
- PD-L1 positive patients had significantly better therapeutic responses with immune checkpoint inhibitor treatment.
Takeaway
This study looked at different medicines for a type of kidney cancer that is hard to treat, finding that some medicines work better than others.
Methodology
The study systematically searched databases for trials and included randomized controlled trials and single-arm studies assessing various treatments.
Potential Biases
There were risks of bias primarily in blinding of participants and personnel, random sequence generation, and allocation concealment.
Limitations
The study's findings are limited by the heterogeneity of nccRCC and the variability in treatment responses across different studies.
Participant Demographics
The study included 398 advanced nccRCC patients, with a mix of histological subtypes.
Statistical Information
P-Value
0.026
Confidence Interval
95% CI: 1.04-1.85
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website